MIR142 (MicroRNA 142)

The expression of ADAMTS5 was down-regulated by H. pylori through regulating a probable pathway (MSTRG.10627.1-miR-142-5p-ADAMTS5). Moreover, down-regulated ADAMTS5 induced PI3K protein, up-regulated phosphorylated AKT protein, and down-regulated p53, which plays an important role in the induction of GC.

In summary, new miRNA signatures of relevance in B-AL and B-Ly could be recognized in this study. Studies in larger cohorts are required to further validate these findings.

Ingenuity Pathway Analysis (IPA) revealed that miR-16-5p and other miRNAs with seed AGCAGCA formed the largest interaction network in GBM, while disease enrichment analysis using Database for Annotation, Visualization, and Integrated Discovery (DAVID) confirmed that the 1000 predicted mRNA targets of DE-miRNAs in GBM were disease relevant. Collectively, these findings identify a robust panel of CSF-derived miRNAs capable of distinguishing IDH-mutant gliomas, GBM, and non-tumor states, supporting the potential of EV-miRNAs as minimally invasive biomarkers for the molecular characterization of diffuse gliomas.

Circulating miRNA profiling showed upregulation of inflammation-associated miRNAs (miR-21-5p, miR-150-5p, miR-142-3p, miR-363-3p), linked through bioinformatic analysis to immune dysregulation, intestinal cancer, and neurotoxicity. Overall, these results indicate that low-dose exposure to pollutant mixtures can induce subtle but biologically relevant immune and epithelial changes, emphasizing the importance of mixture-based approaches in environmental risk assessment.

This review outlines emerging circulating, tissue-derived and imaging biomarker candidates in VS that may complement MRI and support more precise diagnosis, monitoring, and individualized management.

To overcome these barriers, a pH-responsive solid lipid nanoparticle (SLN) system was engineered to co-deliver CB-5083 (a VCP/p97 inhibitor), miR-142 (a PD-L1-targeting microRNA), and imiquimod (R, a TLR7 agonist) for spatially confined induction of endoplasmic reticulum stress (ERS) and immune reprogramming in MSS CRC. Biodistribution analysis confirmed tumor-preferential accumulation with minimal off-target exposure, and biosafety profiling demonstrated low systemic toxicity. This TME-responsive nanoplatform therefore integrates ERS induction, checkpoint modulation, and cytokine suppression to overcome immune exclusion in MSS CRC, representing a clinically translatable strategy for chemo-immunotherapy in immune-refractory tumors.

This investigation established a potential regulatory network, identifying IFITM3 as the downstream target mRNA. The sponging effect of CKMT2-AS1 on miR-142-5p resulted in altered expression levels of IFITM3, subsequently influencing the progression of HCC.

We have identified a potentially novel strategy to enhance CAR-T cell persistence and efficacy in AML by counteracting a leukemia-induced, microRNA-deficiency mediated mechanism of immune suppression.

The microenvironment of dormant metastases shows an increase in T lymphocytes (cytotoxic and helper T lymphocytes and γδ T cells) and neutrophils. Immune-controlled dormant metastases exhibit a unique phenotype that can be exploited to discover new biomarkers, as well as to develop therapies to eradicate them or control overt metastases.

miR-142-3p also showed diagnostic potential through receiver operating characteristic (ROC) analysis (AUC = 0.8481). All the results implied that miR-142-3p can be a candidate biomarker for the early detection and diagnosis of LUAD.

Functional analysis revealed involvement in key NB pathways. Our findings demonstrate that plasma sEV-derived miRNAs represent valuable noninvasive biomarkers for neuroblastoma diagnosis and risk stratification.